SCHEMBL7153222

SCHEMBL7153222

COc1ccc(NS(=O)(=O)CCSc2nc3ccc(OC)cc3s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.53
MAPT P10636 12/20 0.50
LMNA P02545 4/20 0.50
MAPK1 P28482 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
POLB P06746 2/20 0.48
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
CTSK P43235 1/20 0.48
RXFP1 Q9HBX9 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.45
ALOX5 P09917 2/20 0.45
HSD17B10 Q99714 1/20 0.45
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149325 0.95 MAPT (0.53) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7150052 0.94 PDK1 (0.51) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7146179 0.93 PDK1 (0.50) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7151273 0.91 MAPT (0.52) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7153247 0.89 ALDH1A1 (0.59) MAPTLMNAMAPK1L3MBTL1SMN1; SMN2
SCHEMBL7151274 0.89 PDK1 (0.55) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7150971 0.89 MAPT (0.52) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7153219 0.88 PDK1 (0.47) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7151099 0.88 MAPT (0.51) PDK1MAPTLMNAMAPK1L3MBTL1
SCHEMBL7148130 0.86 MAPT (0.46) MAPTLMNAMAPK1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 PDK1 4188/4885MAPT 3839/4885LMNA 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.